Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07120945 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)

Study acronym: Embrace Gyn
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 5 of 5 sites
    v7
  2. Primary completion date changed from estimate of Mar 2026 to Feb 25, 2026v6
  3. Study sites: 4 to 5
    • Primary completion date: Jan 2026 to Mar 2026
    v5
  4. Study sites: 3 to 4v4
  5. Site details revised at 2 of 3 sitesv3
  6. Lead sponsor: [Redacted] to Medtronic - MITGv2 Show 5 more changesShow less
    • Trial status: Withheld to Recruiting
    • Primary completion date: Jan 2026
    • Study completion date: May 2031
    • Start date: Aug 28, 2025
    • Study title shortened, about 3 words
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to evaluate the safety and performance of the investigational Medtronic Hugo™ Robotic Assisted Surgery (RAS) system when used during hysterectomy procedures, including patients being treated for cancer.
Trial Details
NCT Number NCT07120945
Lead Sponsor Medtronic - MITG
Conditions
(from sponsor)		 Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis, Uterine Prolapse, Precancerous/Nonmalignant Condition, Cervical Cancer, Endometrial Cancer +1 more
Related terms Adenomyosis, Endometrial Neoplasms, Endometriosis, Leiomyoma, Menstruation Disturbances, Ovarian Neoplasms, Precancerous Conditions, Uterine Cervical Neoplasms, Uterine Prolapse
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov